Elsevier

Biochemical Pharmacology

Volume 44, Issue 12, 15 December 1992, Pages 2307-2314
Biochemical Pharmacology

Research paper
The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes

https://doi.org/10.1016/0006-2952(92)90674-8Get rights and content

Abstract

Predisposition to idiosyncratic toxicity with carbamazepine is thought to be due to a deficiency of the detoxication enzyme, microsomal epoxide hydrolase, although in some cases, concurrent administration of enzyme inducers might be a contributory risk factor, by altering the critical balance between bioactivation and detoxication. In this study, a mouse model has been used to determine the factors affecting carbamazepine bioactivation, using covalent binding and cytotoxicity as markers of bioactivation in vitro. Microsomes prepared from mice pre-treated with phenobarbitone increased (relative to the control microsomes) the formation of cytotoxic (12.3% vs 3.2%), protein-reactive (3.0% vs 2.0%) and stable (33.8% vs 18.1%) metabolites of carbamazepine. Similarly, pre-treatment with dexamethasone also increased the formation of the cytotoxic (24.8% vs 6.7%), protein-reactive (2.8% vs 1.5%) and stable (38% vs 19.8%) metabolites of carbamazepine, while β-naphthoflavone pretreatment did not increase the formation of either the toxic or stable metabolites of carbamazepine when compared with its control microsomes. Co-incubation with gestodene (10–250 μM) resulted in a dose-dependent inhibition of both the bioactivation of carbamazepine and the formation of its stable 10,11-epoxide. SDS-PAGE and immunoblotting of the microsomes with anti-CYP3A antibody revealed the presence of a 52 kDa protein band in each preparation of microsomes, but the relative intensities of the bands, as measured by laser densitometry, were highest with the phenobarbitone and dexamethasone microsomes. The microsomal oxidation of cortisol to 6β-hydroxycortisol was also enhanced by pretreatment of mice with phenobarbitone (6.5% vs 2.7%) and dexamethasone (8.2% vs 4.3%) but not β-naphthoflavone (2.2% vs 1.6%), when compared with their respective control microsomes, and was inhibited (range 25–68% inhibition), with all the microsomes by gestodene (50 μM). Taken collectively, the data in this study demonstrate that in the mouse, induction of the CYP3A subfamily significantly increases carbamazepine bioactivation. It is likely that in humans inducers of the orthologous form of this enzyme, most notably anticonvulsants, may increase the bioactivation of carbamazepine.

References (63)

  • F.J. Gonzalez et al.

    cDNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment

    Mutat Res

    (1991)
  • P.J. Ciaccio et al.

    Characterization of a phenobarbital-inducible dog liver cytochrome P450 structurally related to rat and human enzymes of the P450IIIA (steroid-inducible) gene subfamily

    Arch Biochem Biophys

    (1989)
  • G. Macphee et al.

    Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction

    Lancet

    (1986)
  • N.H. Shear et al.

    Anticonvulsant hypersensitivity syndrome: in vitro risk assessment

    J Clin Invest

    (1988)
  • M. Pirmohamed et al.

    Carbamazepine hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine

    Br J Clin Pharmacol

    (1991)
  • J.M. Pellock

    Carbamazepine side effects in children and adults

    Epilepsia

    (1987)
  • B.K. Park

    Metabolic basis of adverse drug reactions

    J R Coll Physicians Lond

    (1986)
  • B.K. Park et al.

    Drug disposition and drug hypersensitivity

    Biochem Pharmacol

    (1987)
  • J.J. Sheets et al.

    Ketoconazole: a potent inhibitor of cytochrome P-450 dependent drug metabolism in rat liver

    Drug Metab Dispos

    (1984)
  • R.J. Riley et al.

    Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro

    Br J Clin Pharmacol

    (1989)
  • A.H. Conney

    Pharmacological implications of microsomal enzyme induction

    Pharmacol Rev

    (1967)
  • B.K. Park et al.

    Clinical implications of enzyme induction and enzyme inhibition

    Clin Pharmacokinet

    (1981)
  • R.H. Finnell

    Genetic differences in susceptibility to anticonvulsant drug-induced developmental defects

    Pharmacol Toxicol

    (1991)
  • H.S. Purba et al.

    The metabolism of 17α-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites

    Br J Clin Pharmacol

    (1987)
  • R.J. Riley et al.

    An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil, and mianserin

    Br J Clin Pharmacol

    (1988)
  • S.P. Spielberg

    Acetaminophen toxicity in human lymphocytes in vitro

    J Pharmacol Exp Ther

    (1980)
  • L. Regnaud et al.

    Effect of four-day treatment with carbamazepine at different dose levels on microsomal enzyme induction, drug metabolism and drug toxicity

    Pharmacol Toxicol

    (1988)
  • S.M. Abel et al.

    Cortisol metabolism by human liver in vitro

    Br J Clin Pharmacol

    (1992)
  • U.K. Laemmli

    Cleavage of structural proteins during the assembly of the head of bacteriophage T4

    Nature

    (1970)
  • F.P. Guengerich

    Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene

    Chem Res Toxicol

    (1990)
  • D.W. Nebert et al.

    The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature

    DNA Cell Biol

    (1991)
  • Cited by (50)

    • Transcriptome analysis of the brain of the sea bream (Sparus aurata) after exposure to human pharmaceuticals at realistic environmental concentrations

      2017, Marine Environmental Research
      Citation Excerpt :

      In humans, Brämswig et al. (2002) postulated enzyme-inducing effects of CBZ responsible for changes in lipoprotein concentrations as well as for changes in thyroid and sex hormone concentrations (Connell et al., 1984a,b; Luoma et al., 1985). In addition, CBZ is also known to be a powerful inducing agent of cytochrome P-450 enzymes (Isojärvi et al., 1991; Kerr et al., 1994; Pirmohamed et al., 1992), and its effects on lipoproteins have been largely attributed to its enzyme-inducing action (Luoma et al., 1980; Connell et al., 1984b). Accordingly, considering the significant over-expression of putative “Thyroid hormone receptor and of the putative “Brain cytochrome P450 aromatase (CYP19; see Supplementary file 1), this study suggests similar mechanism of action (MOA) of CBZ in gilthead seabream brain.

    • Effects of carbamazepine and two of its metabolites on the non-biting midge Chironomus riparius in a sediment full life cycle toxicity test

      2016, Water Research
      Citation Excerpt :

      In addition, it caused teratogenic effects in a mouse model and also formed covalent protein adducts in human plasma and liver microsomes, resulting in EP-CBZ being suggested as the cause of these adverse effects (Bennett et al., 1996; Bu et al., 2005). However, cytotoxicity of CBZ showed to increase under trichloropropene oxide treatment, an epoxide hydrolase inhibitor which is also responsible for arene oxide detoxification (Pirmohamed et al., 1992; Riley et al., 1989). On this basis, it was hypothesized that especially arene oxides but also other reactive metabolites of EP-CBZ might be responsible for the toxic effects observed and not EP-CBZ itself (Santos et al., 2008; Shear and Spielberg, 1988).

    • Anticonvulsant agents

      2013, Drug-Induced Liver Disease
    • Effect of pregnane X receptor (PXR) prototype agonists on chemoprotective and drug metabolizing enzymes in mice

      2011, European Journal of Pharmacology
      Citation Excerpt :

      Cytochrome P450 isoform 3A (CYP3A), UDPGT, and GST are known target genes for PXR agonists in human (Duret et al., 2006). In mice, PCN, dexamethasone and SPL were reported to increase Cyp3a mRNA in liver (Maglich et al., 2002; Xu et al., 2005), while, dexamethasone alone increased CYP3A activity (Pirmohamed et al., 1992; Xu et al., 2005). PCN had no effect on the transcript level of Cyp1a1 (Maglich et al., 2002).

    View all citing articles on Scopus
    View full text